Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31073302 | 1.00 | MAPT (0.74) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29435521 | 0.87 | MAPT (0.97) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL15141576 | 0.87 | MAPT (0.97) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL3539759 | 0.87 | MAPT (0.90) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL2722856 | 0.85 | MAPT (1.00) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29437410 | 0.85 | MAPT (1.00) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL2726097 | 0.83 | MAPT (0.72) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL521907 | 0.83 | MAPT (0.72) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29349693 | 0.83 | MAPT (0.72) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL1392957 | 0.83 | MAPT (0.72) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434676-B1 | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-108884101-B | Substituted pyrrolopyrimidine CDK inhibitors, pharmaceutical compositions containing the same and their use | 正大天晴药业集团股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-10570141-B2 | Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-25 | — | — | US | disclosed |
| US-20190300533-A1 | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-10-03 | — | — | US | disclosed |
| EP-3434676-A1 | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570141-B2 | Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof | CDK6, CDK9, CDK3 | MAPT 2175/4885POLB 103/4885RAB9A 3111/4885 |
| US-20190300533-A1 | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | CDK6, CDK9, CDK3 | MAPT 2175/4885POLB 103/4885RAB9A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.